MDxHealth S.A. (MDXH) Research

MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.

Market snapshot

Symbol
MDXH
Price
$0.54
Day change
-3.33%
Market cap
$27.9M
P/E ratio
-1.04x
52-week range
0.51-5.33
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Next earnings
in 2 months
Analyst price target
$4.00

Peer companies

  • Aclaris Therapeutics, Inc. (ACRS)
  • Assembly Biosciences, Inc. (ASMB)
  • Immuneering Corporation (IMRX)
  • NeoGenomics, Inc. (NEO)
  • Quanterix Corporation (QTRX)
  • Shoulder Innovations, Inc. (SI)
  • SANUWAVE Health, Inc. (SNWV)
  • Stereotaxis, Inc. (STXS)

Recent insider activity

  • OConnell Brendan — trade (0 shares) on 2026-05-18
  • Bednarski Eric — trade (0 shares) on 2026-03-18
  • Bellano John — trade (20000 shares) on 2026-03-18
  • Bellano John — trade (65000 shares) on 2026-03-18
  • Bellano John — trade (200000 shares) on 2026-03-18

Open MDxHealth S.A. (MDXH) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.